As weight loss drugs, semaglutide was approved as Wegovy in 2021 and tirzepatide was approved as Zepbound in 2023
In January 2025, the Food and Drug Administration (FDA) approved a brand of semaglutide to reduce the risk of both cardiovascular death and worsening kidney disease in people with Type 2 diabetes and chronic kidney disease
However, the precise effect of GLP-1 on fracture risk has not been unambiguously defined
These are the most frequently reported side effects and often improve after the first few weeks at each new dose
The full prescribing information is available via the electronic medicines compendium
Office Hours: Monday, Tuesday, Wednesday: 9AM5PM Thursday: 9AM6PM (extended hours) Friday: 9AM2:30PM Serving the Entire Tri-Cities Area Located at 3980 Bristol Hwy, Johnson City, TN 37601, Peak Performance is convenient for patients throughout the region including Johnson City, Washington County, Bristol (TN and VA), Kingsport, Sullivan County, Jonesborough, Carter County, Elizabethton, and ETSU students and faculty